Dibekacin

An aminoglycoside antibiotic

Dibekacin

Dibekacin is an aminoglycoside antibiotic used in the treatment of various bacterial infections. It is particularly effective against Gram-negative bacteria and is often used in clinical settings where other antibiotics may not be effective.

Mechanism of Action

Dibekacin works by binding to the 30S subunit of the bacterial ribosome, inhibiting protein synthesis. This action is bactericidal, meaning it kills bacteria rather than merely inhibiting their growth. The binding interferes with the initiation complex of peptide formation, causing misreading of mRNA, which leads to the production of nonfunctional or toxic peptides.

Clinical Uses

Dibekacin is primarily used to treat serious infections caused by susceptible strains of bacteria. These include:

• Sepsis
• Pneumonia
• Urinary tract infections
• Intra-abdominal infections

It is often reserved for use in hospital settings due to its potential for nephrotoxicity and ototoxicity, which are common side effects of aminoglycosides.

Administration

Dibekacin is usually administered via intravenous or intramuscular injection. The dosage and duration of treatment depend on the severity of the infection, the patient's renal function, and the susceptibility of the causative organism.

Side Effects

Common side effects of dibekacin include:

• Nephrotoxicity
• Ototoxicity
• Neuromuscular blockade

Patients receiving dibekacin should be monitored for signs of renal impairment and auditory damage. Dosage adjustments may be necessary in patients with pre-existing renal conditions.

Resistance

Bacterial resistance to dibekacin can occur through several mechanisms, including:

• Enzymatic modification of the drug
• Alteration of the ribosomal binding site
• Efflux pumps that remove the drug from the bacterial cell

Related pages

• Aminoglycoside
• Antibiotic resistance
• Gram-negative bacteria

• 
  Dibekacin